General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.

Oncology Personalized Medicine: Global Patient Group Survey

Access

Costs and patients' ability to access PM therapies are a primary concern among PAGs. Practical treatment guidelines and care pathways are also needed to successfully enable broad patient access to PM therapies and diagnostics.

Early Adoption Policies Necessary to Improve Access

While patient groups surveyed strongly agree that healthcare authorities in their respective countries should implement policies to improve early adoption of personalized medicine…

Early Adoption Policies Necessary to Improve Access

Need for Making Patient Access a Priority

…Patient groups surveyed also think healthcare authorities in their respective countries do not make patient access to innovative cancer treatments a priority…

Need for Making Patient Access a Priority

Patient Groups Not Confident That Patient Access Will Improve

…And patient groups surveyed are not confident healthcare authorities in their respective countries will ensure patient access to new personalized medicines

Patient Groups Not Confident That Patient Access Will Improve

Access to Personalized Therapies Is Lagging

Patient groups surveyed generally agree that patients in their countries have access to diagnostic tests, but access to personalized therapies lags behind

Access to Personalized Therapies Is Lagging

Implementation a Challenge for Patients & Public

Patient groups surveyed identify affordability of treatments, communication with doctors, and locating treatment centers as key challenges for patients and the public in adopting new personalized medicines

Implementation a Challenge for Patients & Public

Implementation a Challenge for Healthcare Community

Patient groups surveyed see developing practical treatment guidelines and instituting screening and diagnostic procedures as key challenges confronting the healthcare community in the adoption of new personalized medicines

Implementation a Challenge for Healthcare Community